Mostrando 10 resultados de: 23
Filtros aplicados
Publisher
Clinical Pharmacology and Therapeutics(3)
Drug Metabolism and Drug Interactions(2)
Pharmacogenomics Journal(2)
Acta Psychiatrica Scandinavica(1)
Clinical Chemistry and Laboratory Medicine(1)
Área temáticas
Farmacología y terapéutica(18)
Enfermedades(16)
Bioquímica(7)
Fisiología humana(4)
Genética y evolución(3)
Área de conocimiento
Farmacología(17)
Genética(9)
Psicopatología(3)
Migración humana(1)
Trastorno depresivo mayor(1)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(20)
ODS 10: Reducción de las desigualdades(15)
ODS 17: Alianzas para lograr los objetivos(12)
ODS 9: Industria, innovación e infraestructura(6)
ODS 1: Fin de la pobreza(2)
Origen
google(3)
High frequency of CYP2D6 ultrarapid metabolizers in Spain: Controversy about their misclassification in worldwide population studies
ArticleAbstract: A high frequency (7-10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has bePalabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Delgado A., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusEvaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: The CEIBA cocktail
ReviewAbstract: Interindividual differences in response to drug treatments are mainly caused by differences in drugPalabras claves:Cocktail, Cytochrome P450 (CYP), Genotype, Hispanics, PhenotypeAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Fiedler J., Francisco J.López Hernández, Galaviz-Hernandez C., Garza-Ocañas L., González-Vacarezza N., Grazina M., Herrera L., Jiménez-Arce G., LARES, Lazalde-Ramos B.P., Leonardo J. Beltrán, López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Natalia Heras, Ochoa-Morales A., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rojas-Martinez A., Rojas-Ponce R., Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusGenomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and predicted phenotypes in 33 nPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusDebrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents
ArticleAbstract: Debrisoquin and S‐mephenytoin hydroxylation phenotypes were determined in 72 Spanish psychiatric patPalabras claves:Autores:Adrián LLerena, Cobaleda J., Dahl M.L., Herraiz A., Johansson I.Fuentes:scopusDebrisoquin oxidation polymorphism in a Spanish population
ArticleAbstract: The capacity for debrisoquin metabolism was determined in 377 healthy Spanish volunteers by measurinPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusDebrisoquine oxidation in schizophrenic patients treated with neuroleptics
ArticleAbstract:Palabras claves:debrisoquine, Neuroleptics, OXIDATION, SchizophreniaAutores:Adrián LLerena, Benitez Rodriguez J., Buemi A.L., Caputi A.P., Cobaleda J., García M.A., Piña B., Spina E.Fuentes:scopusDebrisoquine oxidation phenotype in psychiatric patients.
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., García M.A., Martínez C., Piñas B.Fuentes:scopusDetermination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: Application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship
ArticleAbstract: The drug-metabolizing cytochrome P450 (CYP) enzyme CYP2D6 is involved in the metabolism of several cPalabras claves:CYP2D6, debrisoquine, HPLC, Metabolic ratioAutores:Adrián LLerena, Berecz R., Cáceres M.C., Cobaleda J., Dorado P., González I.Fuentes:scopusDEBRISOQUINE HYDROXYLATION PHENOTYPES IN HEALTHY VOLUNTEERS
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusClinical implementation of pharmacogenetics and personalized drug prescription based on e-health: The MedeA initiative
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Mata-Martín C., Penãs-Lledó E.M., Pijierro A., Sánchez C.L.Fuentes:scopus